Final Results of a Phase II Multicenter Trial of HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab Combination Treatment in Patients with Stage IIIB-IV Unresectable or Metastatic Melanoma

Abstract #166420

Robert H.I. Andtbacka¹, Merrick I. Ross², Sanjiv S. Agarwala³, Matthew H. Taylor⁴, John T. Vetto⁴, Rogerio I. Neves⁵, Adil Daud⁶, Hung T. Khong¹, Richard S. Ungerleider⁷, Maki Tanaka⁸, and Kenneth F. Grossmann¹ ¹Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; ²The University of Texas MD Anderson Cancer Center, Easton, PA; ⁴Knight Cancer Institute, Oregon Health and Science University, Portland, OR; ⁵Penn State Hershey Cancer Institute, Hershey, PA; ⁶UC San Francisco, San Francisco, CA; ⁷Theradex Oncology, Princeton, NJ; ⁸TaKaRa Bio. Inc, Shiga, Japan

INTRODUCTION

HF10 is a bioselected replication-competent oncolytic virus derive from HSV-1. In preclinical studies, combining ipilimumab (CTLA-4 antibody) with HF10 has shown a higher rate of complete tumor disappearance and significant improvement in the median overall survival compared with either HF10 or ipilimumab alone. The current Phase II trial of HF10 and ipilimumab combination treatment was designed to assess the efficacy and safety of patients with Stage IIIB, IIIC, or IV metastatic malignant melanoma.

PHASE II STUDY DESIGN

STUDY OBJECTIVES

Evaluate the efficacy, safety and tolerability of HF10 at 1×10^7 TCID₅₀/mL in combination with 3mg/kg ipilimumab (ipi) in patients with Stage IIIB, Stage IIIC, or Stage IV unresectable or metastatic malignant melanoma

ENDPOINTS

PRIMARY:

• Best overall response rate (BORR) at Week 24

SECONDARY:

- Safety and tolerability
- Objective response rate (ORR) at Weeks 12, 18, 24
- Progression-free survival (PFS)
- Durable response rate (DRR)
- 1-year survival rate
- Evaluation of correlative studies

KEY INCLUSION CRITERIA

- Stage IIIB, IIIC or IV unresectable/unresected or histologically confirmed diagnosis of metastatic malignant melanoma
- Measurable (mWHO & irRC) superficial tumor suitable for injection
- Ipilimumab-eligible patients including patients previously treated with antitumor agents other than i.v. Ipilimumab.
- Adequate hepatic, renal, bone marrow function
- ECOG 0, 1, 2
- Life expectancy \geq 24 weeks
- No known bleeding diathesis or coagulopathy

STUDY TREATMENT

- Intratumoral injection of HF10 at 1×10^7 TCID₅₀ /mL in combination with intravenous infusions of 3mg/kg ipilimumab
- Up to 5.0mL of HF10, the injection volume to be adjusted based on the size of tumor mass

Γ	Ipilimumab 3mg/kg IV q3wks x 4						
	1 1	1 1	l .	l			
	3 weeks	3 weeks	3 weeks	3 weeks	1 year		
I .	HF10 1x10 ⁷ T	-	q1wk x 4 wks	-	up to 45 wks		

Table 1: Safety Summ

Treatment-Emergent Adverse (TEAEs)

Safety evaluable patients With any TEAEs With any TEAEs related to HF10 With severity \geq Gr 3 for HF10 related With any TEAEs related to Ipilimumab With severity ≥ Gr 3 for Ipilimumab re With any serious, HF10 related TEAEs With any serious, Ipilimumab related Who discontinued drug due to HF10 r

Table 2: Responses in the Efficacy Evaluable Population

Best Overall Response (N=4

Overall Response (irCR + irPR)

Disease Stability rate (irCR

+irPR+irSD)

Complete Response (irCR)

Partial Response (irPR)


Stable Disease (irSD)

Unconfirmed Progressive Diseas

(unconfirmed irPD)


Confirmed Progressive Disease (confirmed irPD)


Figure 1: Best Overall Response at 24 Weeks



nary						
e Events		ber of nts (%)				
	4	6				
	46	(100%)				
	42	(91%)				
TEAEs	3	(6.5%)				
)	43	(93%)				
elated TEAEs	10	(22%)				
	2	(4%)				
TEAEs	10	(22%)				
related TEAEs	0	(0%)				

4)	24 weeks (N%)	48 weeks (N%)	
	18 (40.9%)	20 (45.5%)	
	30 (68.2%)	30 (68.2%)	
	8 (18.2%)	8 (18.2%)	
	10 (22.7%)	12 (27.3%)	
	12 (27.3%)	10 (22.7%)	
ise	11 (25.0%)	11 (25.0%)	
	3 (6.8%)	3 (6.8%)	





PHASE II OVERALL RESULTS

2017 American Society Clinical Oncology Conference